Valuation dashboard for Bio-Rad Laboratories, Inc. (BIO) with P/E 45.11, P/B 1.39, EV/EBITDA 20.67 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics.
Analysis Summary
Bio-Rad Laboratories, Inc. reported revenue of $2.58B in the most recent fiscal year, growing at a 5-year CAGR of 0.3%. Net income reached $759.9M, with a -27.6% 5-year CAGR.
Trailing-twelve-month margins: gross margin 51.9%, operating margin 9.1%, net margin 8.6%.
At $372.18 (closing price, October 30, 2026), BIO trades at a P/E of 45.11 and an ROE of 3.15%. Market capitalisation stands at $10.0B.
Balance sheet quality for BIO: current ratio of 5.6. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 45.11 |
| Price / Book | 1.39 |
| EV / EBITDA | 20.67 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-171.28 |
| vs Current Price | -146.0% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| BIO | Bio-Rad Laboratories, Inc. | $10.0B | 45.11 | 1.39 | 3.2% |
| TECH | Bio-Techne Corporation | $11.4B | 62.64 | 5.38 | 8.9% |
| RGEN | Repligen Corporation | $11.2B | 4.78 | -0.6% | |
| BRKR | Bruker Corporation | $8.7B | 3.62 | -2.9% | |
| MRVI | Maravai LifeSciences Holdings, Inc. | $2.2B | 5.65 | -35.4% | |
| TMO | Thermo Fisher Scientific Inc. | $257.7B | 36.76 | 4.71 | 13.3% |
| DHR | Danaher Corporation | $163.3B | 38.01 | 3.05 | 8.2% |
| RVTY | Revvity, Inc. | $17.5B | 74.76 | 2.43 | 3.3% |
Price
| Price | $372.18 (closing price, October 30, 2026) |
| Market Cap | $10.0B |
| Exchange | NYSE |
| Country | US |
Profitability
| Return on Equity | 3.15% |
| Return on Invested Capital | 1.54% |
| Return on Assets | 2.17% |
| Gross Margin | 51.90% |
| Operating Margin | 9.08% |
| Net Margin | 8.59% |
Related companies: TECH · RGEN · BRKR · MRVI · TMO · DHR · RVTY
Explore sector: Healthcare · Medical - Devices
More sections of BIO: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks